文献速递瓣膜外科

美国65岁以下患者经导管与外科主动脉瓣置换对比

Transcatheter versus surgical aortic valve replacement in patients younger than 65 years in the United States.
PubMed 文献 · J Thorac Cardiovasc Surg · 2025-01-09

该回顾性分析纳入2013至2021年加州、纽约州和新泽西州9557例接受生物主动脉瓣置换的<65岁主动脉瓣狭窄患者,比较经导管与外科置换的趋势及结局。倾向评分匹配后,经导管组6年死亡率更高(23.3% vs 10.5%,HR 2.27,95%CI 1.82-2.83,P<.001),30天新起搏器植入率更高(10.7% vs 6.2%,P<.001),30天死亡率无差异。

要点

  • <65岁患者经导管主动脉瓣置换比例从2013年7.1%升至2021年54.7%。
  • 匹配后经导管组6年死亡率显著高于外科组(23.3% vs 10.5%)。
  • 经导管组30天新起搏器植入率更高(10.7% vs 6.2%)。

核心结论

  • 尽管有临床指南,<65岁患者经导管主动脉瓣置换使用增加,且与匹配外科生物瓣置换队列相比6年死亡率和永久起搏器植入率更高。

研究设计与样本

  • 回顾性分析纳入2013至2021年加州、纽约州和新泽西州9557例接受生物主动脉瓣置换的<65岁主动脉瓣狭窄患者,按经导管或外科置换分层,倾向评分匹配后采用Cox比例风险模型和Fine-Gray模型比较结局。

主要发现

  • <65岁患者经导管主动脉瓣置换比例从2013年7.1%增至2021年54.7%。
  • 匹配后30天死亡率两组相似(1.0% vs 1.5%,P=.33)。
  • 经导管组6年死亡率更高(23.3% vs 10.5%,HR 2.27,95%CI 1.82-2.83,P<.001)。
  • 经导管组30天新起搏器植入率更高(10.7% vs 6.2%,P<.001)。
  • 6年卒中、心衰住院或再手术累积发生率无差异,多项敏感性分析证实上述发现。

临床怎么用

  • 对<65岁主动脉瓣狭窄患者选择经导管主动脉瓣置换时需权衡较高的6年死亡率和起搏器植入风险。
  • 需开展随机对照试验比较<65岁患者经导管与外科主动脉瓣置换的长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The study objective was to characterize the trends and outcomes of aortic valve replacement in patients aged less than 65 years with aortic stenosis between 2013 and 2021. METHODS: This retrospective analysis included 9557 patients who underwent biological aortic valve replacement in California, New York, and New Jersey from 2013 to 2021. Patients were stratified by approach: transcatheter aortic valve replacement versus surgical aortic valve replacement. Our primary outcomes were 30-day and 6-year mortality and morbidity (stroke, heart failure rehospitalization, reintervention, and new pacemaker implantation). After propensity score matching, Cox proportional hazard and Fine-Gray models were used to compare outcomes after transcatheter aortic valve replacement and surgical aortic valve replacement. RESULTS: The proportion of patients aged less than 65 years with aortic stenosis undergoing transcatheter aortic valve replacement versus surgical aortic valve replacement increased from 7.1% in 2013 to 54.7% in 2021. After propensity score matching, 30-day mortality was similar between both groups (1.0% vs 1.5%, P = .33). Transcatheter aortic valve replacement had a higher 6-year mortality (23.3% vs 10.5%, hazard ratio, 2.27; 95% CI, 1.82-2.83; P < .001). The 30-day rate of new pacemaker implantation was higher after transcatheter aortic valve replacement (10.7% vs 6.2%, P < .001). There was no difference in the 6-year cumulative incidence of stroke, heart failure hospitalizations, or reoperations. Multiple sensitivity analyses confirmed these findings. CONCLUSIONS: Despite clinical guidelines, the use of transcatheter aortic valve replacement has increased in patients aged less than 65 years. Transcatheter aortic valve replacement in this population is associated with a higher 6-year mortality and a higher rate of new permanent pacemaker implantation when compared with a matched cohort treated with biologic surgical aortic valve replacement. These findings support the need for a randomized controlled trial comparing long-term outcomes of transcatheter aortic valve replacement versus surgical aortic valve replacement in patients aged less than 65 years.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Alabbadi S, Bowdish ME, Sallam A, et al. Transcatheter versus surgical aortic valve replacement in patients younger than 65 years in the United States. J Thorac Cardiovasc Surg. 2025. PMID: 39798896. doi:10.1016/j.jtcvs.2024.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。